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Abstract Disease specific patterns of volatile organic
compounds can be detected in exhaled breath using an
electronic nose (e-nose). The aim of this study is to explore
whether an e-nose can differentiate between head and neck,
and lung carcinoma. Eighty-seven patients received an
e-nose measurement before any oncologic treatment. We
used PARAFAC/TUCKER3 tensor decomposition for data
reduction and an artificial neural network for analysis to
obtain binary results; either diagnosed as head and neck or
lung carcinoma. Via a leave-one-out method, cross-vali-
dation of the data was performed. In differentiating head
and neck from lung carcinoma patients, a diagnostic
accuracy of 93 % was found. After cross-validation of the
data, this resulted in a diagnostic accuracy of 85 %. There
seems to be a potential for e-nose as a diagnostic tool in
HNC and lung carcinoma. With a fair diagnostic accuracy,
an e-nose can differentiate between the two tumor entities.
Keywords Volatile organic compounds  Electronic
nose  Head and neck carcinoma  Lung carcinoma 
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Introduction
Head and neck squamous cell carcinoma (HNSCC) and
lung cancer have a major impact on global health. In 2012,
a worldwide estimate of 686,000 and 1,825,000 new cases
of head and neck and lung cancer were diagnosed each
year, respectively, with an estimated death rate of 5 and
19 %, respectively [1]. Early diagnosis improves prognosis
considerably [2–4], however, diagnosis of HNSCC and
lung cancer is rather invasive, since the gold standard is
histopathology with biopsies which have to be obtained
through bronchoscopy, or endoscopy of the head and neck
area. Therefore, a non-invasive diagnostic tool might be
useful in this population. Moreover, differentiating
between primary lung malignancies and metastases to the
lung of head and neck origin could aid in therapy decision
making.
In the past decades, Volatile Organic Compounds
(VOC’s) were broadly investigated as diagnostic
biomarkers in medicine. Using sniffer dogs, gas chro-
matography, mass spectroscopy or pattern recognition,
VOC’s can be detected in exhaled breath, feces or urine to
diagnose various diseases [5–7]. One device to investigate
VOC patterns is an electronic nose (e-nose). In exhaled
breath, Dragonieri et al. [8] compared VOC patterns of
patients with lung cancer, COPD, and healthy controls
using an e-nose and concluded that, with an accuracy of
85–90 %, VOC patterns of these groups differ signifi-
cantly. For HNSCC, our group [7] evaluated VOC patterns
in exhaled breath of 36 HNSCC patients and 23 patients
without malignant disease with an e-nose and revealed a
90 % sensitivity and 80 % specificity in diagnosing
HNSCC.
Peng et al. [9] used an e-nose to differentiate between
lung, breast, prostate and colon carcinoma in a proof of
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concept study with VOC pattern recognition. They con-
cluded that different cancer types have different VOC
patterns. To our knowledge, no studies have been published
regarding the possibility of VOC pattern recognition to
differentiate HNSCC and lung carcinoma. As HNSCC and
lung carcinoma are both part of the respiratory tract and
share some risk factors like smoking, radiation exposure
and exposure to certain carcinogens like asbestos, it would
be interesting to know whether an e-nose can discriminate
between both cancer types [10, 11]. Moreover, as a syn-
chronous second primary lung tumor occurs in 0.8 % of
cases in HNSCC [12], an e-nose could possibly help
detecting second primary tumors or differentiate between
metastases or primary malignancies. Therefore, the pur-
pose of this study is to determine whether VOC pattern
recognition can discriminate between breath of primary
HNSCC patients and primary lung carcinoma patients
using a non-invasive e-nose.
Materials and methods
Participants
For this study, patients with suspect primary HNSCC or
lung carcinoma were recruited in a tertiary care referral
hospital; the Maastricht University Medical Centre
(MUMC). Exclusion criteria were: age under 18 years,
current tracheostomy, having had any treatment for current
tumor, and a history of any other form of cancer. Patients
were also excluded if they did or could not complete the
full 5 min of measurement or were unable to endure a nose
clip during measurement to promote oral breathing through
the e-nose. Cutaneous tumors or malignancies of the sali-
vary glands were excluded in this study. Tumor charac-
teristics and medical history were collected from the
clinical records.
Breath analysis can be influenced by internal and
external pollution of the exhaled breath [13]. To minimize
external pollution of ambient air in the room in which the
measurement is performed, the lungs are rinsed with clean
filtered air during measurement. Minimizing internal fac-
tors is more difficult since local factors in the gastro-in-
testinal and upper and lower respiratory tract can contribute
to the VOC’s in the exhaled air [13]. Moreover, metabo-
lites in the blood due to, e.g., starvation or oxidative stress
due to smoking can be excreted in urine or exhaled breath
[13–15]. Therefore, we documented metabolic fasting state
and smoking habits in this study to take into consideration
in this study. Metabolic fasting state was defined as no food
or drinks 4 h before the measurement with the exception of
two units of clear liquids 2 h before the measurement. Non-
smoking was defined as no smoking in the previous month.
Side- or adverse-effects during or shortly after mea-
surement were documented. Oral informed consent was
obtained from all patients. The study protocol was
approved by the medical ethics committee in accordance of
the declaration of Helsinki.
Study design
All patients were asked to in- and exhale through the
e-nose for 5 min. Before the measurement, patients were
instructed to get acquainted with the e-nose by performing
some test in- and exhalations. A nose clip was placed on
the nose to avoid entry of non-filtered air. Patients were
instructed to enclose the lips over the mouthpiece at all
times.
E-nose measurements were performed in parallel with
the regular diagnostic work-up. However, participants did
not receive any diagnostic results from the e-nose mea-
surement. The routine diagnostic work-up was based on
national cancer guidelines from the Dutch Head and Neck
Society and independent of e-nose measurements. E-nose
outcomes were compared to histopathology of biopsies.
Materials
The e-nose used in this study, (Aeonose, the eNose Com-
pany, Zutphen, the Netherlands), consists of three micro
hotplate metal oxide sensors (AS-MLV sensors, Applied
Sensors GmbH). During the measurement the hotplate will
be periodically heated and cooled between 260 and 340 C
in 32 steps, during which they are exposed to the exhaled
breath. The reduction and oxidation (redox) reactions of the
VOC’s at the surface of the metal oxide sensors result in a
change in conductivity of the sensors. These changes in
conductivity over time, with altering temperature create a
unique pattern of redox-reactions of the VOC’s.
A measurement cycle lasts for about 15 min, of which
5 min of in- and exhalation by the patient takes place.
Patients breath through the Aeonose via a disposable
mouthpiece with a high efficiency particulate arrestance
(HEPA) filter to protect the Aeonose against contamination
by, e.g., bacteria and viruses. After this, patients inhale
through a carbon filter and a valve to filter the environ-
mental air of disturbing VOC’s, which may tamper with the
measurement.
The first 2 min of the measurement cycle is used to rinse
patient’s lungs with clean filtered air and remove dead air
space. Rinsing the lungs minimizes the possible external
confounding factors of the air in the room where the
measurement is being performed. During the next 3 min,
patient’s exhaled breath is analyzed by the sensors. A small
pump ensures a constant flow of exhaled air passing the
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sensor surface and a Tenax tube. The combination of
sensors and the Tenax tube ensures an optimal detection of
the VOC’s present, even at a low VOC concentration. After
the patient has put the Aeonose down, regeneration of the
sensors takes place using filtered environmental air passage
through the carbon filter and subsequently the Tenax tube
is heated to detect possible low concentrated VOC’s in the
exhaled breath. Finally, the sensors are regenerated again
using filtered air.
Statistical analysis
Differences in baseline characteristics were determined
using independent sample t test, Fisher’s exact test, or
Pearson’s Chi-square test. All statistical analyses were
performed using IBM SPSS Statistics for Windows, Ver-
sion 23.0 (Armonk, NY: IBM Corp.).
Each e-nose measurement results in 32 (temperature)
times 36 (measurement cycles) times 3 (sensor) data points,
which can be regarded as a 3-dimensional multi-way dataset
of temperature versus time versus sensor type, respectively.
First, the data are being compressed through PARAFAC/
TUCKER3 tensor decomposition. Secondly, the remaining
vectors representing the coded patient information are
analyzed by an artificial neural network (ANN). This is
being executed for a number of data scaling options
resulting in 21 different designs for separating ‘sick’ and
‘healthy’ individuals. The ANN is per protocol based in this
proof of concept study to exclude possible imperfections of
the data. Patients were excluded from the analysis when
being falsely diagnosed in 85 % of used designs. Data
compression and ANN have been integrated in a proprietary
software package (Aethena, the eNose Company, Zutphen,
the Netherlands). The binary results are presented in a
scatterplot and a receiver operating characteristic curve
(ROC-curve). Matthews Correlation Coefficients (MCC)
were calculated to measure the quality of binary classifi-
cations and 95 % confidence intervals (CI) were given.
All data were premarked with the diagnosis of either
HNSCC or lung carcinoma when processed in Aethena. A
best fit model of the data was calculated. To predict the fit of
a model for future undefined breath samples, cross-valida-
tion of the data was performed using a leave-one-out
method. This internal validation prevents to a high extent
fitting of data on artifacts instead of breath profile classifiers.
Results
Patient characteristics
This study included eighty-seven patients with histo-
pathological proven HNSCC (N = 53) or lung carcinoma
(N = 34). Three patients were excluded from analysis,
since they were assigned to the wrong group in over 85 %
of the tested designs by the per-protocol-based ANN.
These three patients included a T2N0M0 squamous cell
carcinoma of the oral cavity, and two stage IV lung car-
cinoma patients (adenocarcinoma and neuroendocrine
tumor). Baseline characteristics of the included patients are
listed in Table 1. Only food intake in the past 4 h revealed
significant baseline group differences. Five Aeonoses were
used to perform the measurements to exclude possible
machine-bound confounding factors. Tumor sites of
included HNSCC patients were oral cavity (N = 15),
oropharynx (N = 13), nasopharynx/nasal cavity (N = 2),
hypopharynx (N = 3), and larynx (N = 19) and all patients
were diagnosed with squamous cell carcinoma. Of the
patients with lung carcinoma, five patients were diagnosed
with squamous cell carcinoma, eighteen with adenocarci-
noma, three with small cell carcinoma, and six with other
malignancies (malignant mesothelioma, neuroendocrine
tumor). Using Pearson’s Chi-square we found significant
(0.000) baseline differences between histopathology of
included head and neck to lung carcinoma patients. The
distribution of tumor-stage amongst both groups is dis-
played in Table 1. Significant baseline differences between
both groups were found, where lung carcinoma patients
usually have more advanced disease compared to HNSCC
patients. Two patients with lymph node metastasis of
Table 1 Baseline characteristics of included patients
Lung Head and Neck p value
No. of patients 32 52
Age (years) 65 63 0.362#
Sex (male) 20 43 0.068^
Food intake\4 h (Yes) 30 28 (12 unknown) 0.001*
Currently smoking 13 32 0.074^







I 4 (13 %) 16 (32 %)
II 1 (3 %) 10 (20 %)
III 10 (32 %) 5 (10 %)
IV 16 (52 %) 19 (38 %)
Missing data 1 2
No number
* Pearson Chi-square
^ Fisher’s exact test
# Independent t test
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initially unknown primary tumors were found. Most indi-
vidual patient characteristics including TNM-stage are
listed in the online resources, where patient numbers cor-
respond with the numbers in Figs. 1 and 2 (Online
Resource 1).
Three patients reported a feeling of dyspnea at the end
of the measurement and shortly after. No additional follow-
up or intervention was needed for all three patients. No
other side- or adverse-effects were reported.
Data analysis
Figure 1 displays a scatterplot of individual predictive
values of a best fit of the data analyzed by the ANN. To
obtain the best possible diagnostic accuracy of this data,
the threshold was set to 0.55. This resulted in six patients
being classified in the wrong group, with a sensitivity of
96 % and specificity of 88 %, and an overall accuracy of
93 % (MCC: 0.85) in differentiating between lung
carcinoma and HNSCC. Cross-validation data is displayed
in Fig. 2. The threshold for this scatterplot was set to 0.63
to obtain the best possible diagnostic accuracy. A sensi-
tivity of 85 % and specificity of 84 % was calculated with
thirteen patients being misclassified. This results in an
overall accuracy of 85 % with an MCC of 0.70. The ROC-
curve in Fig. 3 illustrates the different sensitivities and
specificities with altered thresholds of both the best fit of
the data as the cross-validation. The area under the curve
(AUC) is 0.98 (95 % CI 0.96–1.00) and 0.88 (95 % CI
0.81–0.95), respectively.
Discussion
In this proof of concept study, we have studied whether an
e-nose can distinguish breath samples of patients with
HNSCC from samples of patients with lung carcinoma.
Given the high sensitivity and specificity for best fit of data
Fig. 1 Scatterplot of best of fit
of data
Fig. 2 Scatterplot of cross-
validation of the data
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and the leave-one-out cross-validation within this dataset,
we conclude an e-nose can accurately differentiate between
breath samples of patients with either tumor.
There is a growing interest in the use of VOC pattern
recognition in diagnosing head and neck, and lung diseases.
Chapman et al. [16] evaluated twenty patients with malig-
nant mesothelioma with an e-nose in a cross-sectional case–
control study and could successfully differentiate between
mesothelioma and the 42 included healthy controls (sensi-
tivity 90 %, specificity 91 %). D’amico et al. [17] evaluated
an e-nose in patients with a vast range of lung carcinoma
histopathological origins (N = 28) and patients with other
benign lung conditions (N = 28) and found a correct clas-
sification of patients in 85.7 % of cases. In analyzing
HNSCC, Gruber et al. [18] analyzed breath samples of 22
patients with malignant larynx and pharynx tumors, 21
patients with benign larynx and pharynx tumors, and 19
healthy controls, with an e-nose. HNSCC patients could be
distinguished from healthy controls as well as from benign
tumors with a sensitivity of 77 %, specificity of 90 % and
overall accuracy of 83 %. In the differentiation of diseases
with an e-nose, the current study adds the differentiation
between two distinct oncologic entities. With an internal
cross-validation of the data, we have found a sensitivity of
85 % and specificity of 84 % in differentiation HNSCC and
lung carcinoma breath samples.
Although several studies report the use of an e-nose in
lung or head and neck disease, different types of sensors
are used in literature to observe VOC patterns, such as
quartz crystal [17, 19], conducting polymers [8, 16], and
metal oxide sensors [7, 9, 18], as used in the current study.
This makes results of individual studies using e-nose
technology hard to compare. Yet, regardless of the type of
sensors used, most studies reveal promising results for
VOC pattern recognition as a diagnostic tool.
VOC’s are a group of hydrocarbons such as benzene and
methane. Formation of these VOC’s are found in various
basic cellular functions such as oxidative stress and energy
metabolism [20]. Besides that, VOC’s can originate from
exogenous origin such as cigarette smoke, which can change
the exhaled VOC pattern by itself or due to interaction with
the human tissue [21]. With the current e-nose technique
used, it remains unclear what pattern of VOC defines lung
carcinoma and what defines head and neck carcinoma.
Tumor growth is associated with changes in gene expression
and protein changes, and associated with oxidative stress
and altered metabolism. Therefore, tumor growth in general
is associated with altered VOC concentrations. As men-
tioned earlier Peng et al. [9] revealed that different origins of
cancer result in different patterns of VOC’s. This study
confirms that different tumor sites result in different VOC
patterns. This suggests that VOC’s produced by processes
involved in tumor growth are different for other origins of
cancer. The statement that different origins produce differ-
ent VOC’s, might be emphasized by the increased concen-
trations of methylated alkanes in exhaled breath in lung
cancer [22] and increased concentrations of sulfur and
cyanide-containing compounds in headspace of gastric
content in gastro-esophageal cancer [23].
This study indicates that the e-nose might be a valid tool
in the diagnostic work-up for HNSCC or lung carcinoma.
Our hypothesis is that in future clinical practice, an e-nose
Fig. 3 Receiver operating
characteristic curve
Eur Arch Otorhinolaryngol (2016) 273:3897–3903 3901
123
might be used as a tool to detect and differentiate syn-
chronous primary lung carcinoma or metastases in patients
with primary HNSCC. However, no patients were included
with both primary lung carcinoma and primary HNSCC.
Besides that, an e-nose might be a tool to detect primary
tumors in patients with lymph node metastasis from
unknown primary tumors. Although this study included
only two patients with initially unknown primary lung
carcinoma, both patients were correctly classified as having
primary lung carcinoma. However, a larger blinded study
population is necessary, to incorporate an e-nose in the
diagnostic work-up for head and neck or lung carcinoma.
Limitations
Due to the explorative character of this study, several
limitations are in order. Therefor these results should be
considered preliminary. A possible limitation of this study
are the irregularities of the use of a neural network to
calculate the predictive values of both groups. As with
other statistical modalities to process large multi-way
datasets such as factor analysis or principal component
analysis, the model created may be partially based on
artifacts in the dataset, instead of the main obvious group
difference of different tumor origin. Although cross-vali-
dation revealed high sensitivity and specificity, indicating a
high generalizability of the data, a large blinded dataset
should be added in the future, to confirm the diagnostic
accuracy of blinded data in an e-nose to differentiate
between HNSCC and lung carcinoma. With this larger
study population, cofactors such as history of nicotine
abuse and TNM-stage can be taken into consideration in
the analysis.
Some baseline characteristics were significantly differ-
ent comparing both groups. The lung carcinoma groups
contained mainly more advanced tumor-stages and were
less often in a fasted state than the HNSCC group. More-
over, only squamous cell carcinoma patients were included
in the head and neck group, whereas the lung group con-
sists of five different histopathological origins. Although
this is the natural variation in patients visiting the outpa-
tient clinic [24], this too might influence outcomes in this
dataset.
Conclusion
This study reveals that there seems to be a potential for an
e-nose as a diagnostic tool in HNSCC and lung carcinoma.
With a diagnostic accuracy of 93 % and cross-validation of
85 %, an e-nose can differentiate between breath samples
of patients with HNSCC and lung carcinoma. Future
blinded studies with a larger study population should
determine whether an e-nose can be incorporated in the
diagnostic work-up for HNSCC and lung carcinoma.
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